目的 分析启东市人民医院2016年活血化瘀类中成药用药情况，为临床安全用药提供指导。方法 收集启东市人民医院2016年活血化瘀类中成药的出库数据以及上报的不良反应报告。对药品种类、销售金额、用药频度（DDDs）、日均费用（DDC）、排序比（B/A）和不良反应的类型、科室分布进行统计、排序和分析。结果 2016年启东市人民医院活血化瘀类中成药分布科室以心内科、神经内一科和神经内二科为主，分别占26.11%、16.91%、15.13%。活血化瘀类中成药销售额最高的是舒血宁注射液，DDDs最高的是血府逐瘀片，DDC最高的是丹红注射液，大部分药品的B/A值偏离1，表明市场份额和用药选择一致性较差。34例（2.52%）发生不良反应，注射剂有27例，非注射剂7例。结论 启东市人民医院活血化瘀类中成药临床应用仍存在一定的不合理情况，需要采取一些干预措施。

Objective To analyze the clinical application of blood circulation category of Chinese patent medicine in Qidong People's Hospital in 2016, in order to provide guidance for clinical medication. Methods The database about blood circulation category of Chinese patent medicine was collected in Qidong People's Hospital in 2016, and the adverse drug reaction reports were also collected. The drug varieties, sales amount, defined daily doses (DDDs), average daily cost (DDC), sorting ratio (B/A), the types and department distribution of adverse reaction were analyzed and sorted. Results The three most distribution departments of blood circulation category of Chinese patent medicine were cardiology department, 1st neurology department and 2nd neurology department in Qidong People's Hospital in 2016, accounted for 26.11%, 16.91% and 15.13%, respectively. The drug with the highest sales amount was Shuxuening Injection. DDDs of Xuefu Zhuyu Tablets were the highest. DDC of Danhong Injection was the highest. The B/A values of most drugs were far from 1, showing poor consistency between market share and drug choice. There were 34 cases (2.52%) adverse reactions, including 27 cases of injection and 7 cases of no-injection. Conclusion There are still some unreasonable situations of blood circulation category of Chinese patent medicine in Qidong People's Hospital in 2016, which needs to take some intervention measures.